In patients with RA.

Bacterial, non-human forms of the dnaJP1 peptide included the same sequence of RA-susceptible HLA amino acids also, and were discovered by the UCSD group to be targets of pro-inflammatory T cell responses in RA patients. Related StoriesResearchers develop novel technology for chronic arthritisArthritis increases risk of falling into poverty, new study showsYoga enhances physical, mental wellbeing of individuals living with common forms of arthritis Consequently, we believed that if we’re able to administer the bacterial dnaJP1 as a vaccine to individuals with early RA, it would affect the autoimmune swelling, Albani said.Our joint solutions can help enhance patient recruitment, retention, and compliance, three critical regions of concern for our customers highly. Tim Davis, CEO of Exco InTouch describes the relationship as the perfect integration of complementary technology products, adding we are delighted to utilize Almac’s clinical technologies business on such a robust cellular and interactive response alternative. Rarely do you have an opportunity to hire a solution that will assist all trial participants, the sponsor, the site, and the individual. Our clients are already looking forward to taking advantage of this original Almac-Exco InTouch offering.